pharma · Myotonic Dystrophy type 1 and type 2 (DM1/DM2) · Non-Dystrophic Myotonias (NDM)
Lupin (Europe)
Lupin Europe GmbH
Lupin (Europe) clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- EU
- Employees
- 37
- Programs
- 4
- Drugs
- 9
- Patents
- 0
Lupin (Europe) projects
4 ClinicalTrials.gov programs sponsored by Lupin (Europe).
Lupin (Europe) has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
MEX-DM-302
Lupin Europe GmbH
Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
1 trial -
MEX-DM-303
Lupin Europe GmbH
Myotonic Dystrophy type 1 and type 2 (DM1/DM2)
1 trial -
MEX-NDM-301
Lupin Europe GmbH
Non-Dystrophic Myotonias (NDM)
1 trial -
MEX-NM-303
Lupin Europe GmbH
Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)
1 trial
Frequently asked questions
How many clinical projects does Lupin (Europe) have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.